QTERN (saxa/dapa) EU approved for type-2 diabetes This

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
QTERN (saxa/dapa) EU approved for type-2 diabetes

This announcement contains inside information 19 July 2016 14:15 ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES AstraZeneca today announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe. Qtern is indicated for adults with type 2 diabetes aged 18 years and older to improve glycaemic control when metformin and/or sulphonylurea and one of the mono-components of Qtern alone do not provide adequate control, or when a patient is already being treated with the free combination of saxagliptin and dapagliflozin. Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development at AstraZeneca said: "Nearly half of all people with type 2 diabetes are unable to reach their treatment goal and so risk developing complications due to hyperglycaemia. Qtern is the first combination product of its kind approved in Europe and an important new treatment option to help patients reach their goals through powerful HbA1c reduction." The approval is based on data from three trials in type 2 diabetes submitted to the European Medicines Agency. In two trials, the combination of saxagliptin and dapagliflozin with metformin resulted in statistically significant reductions in HbA1c in comparison to patients treated with placebo. An additional trial showed that the combination of saxagliptin and dapagliflozin added to metformin resulted in statistically superior reductions in HbA1c in comparison to patients treated with saxagliptin or dapagliflozin alone added to metformin. In these trials, the safety profile of Qtern was similar to the known safety profiles of saxagliptin and dapagliflozin. About AstraZeneca in Diabetes AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes. Our current portfolio consists of the three newest classes of non -insulin, anti-diabetic treatments that support individualised treatment approaches: SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. As a main therapy area for the company, we are focusing our research and development efforts on diverse populations and patients with significant co -morbidities, such as cardiovascular disease, obesity, non-alcoholic steatohepatitis (NASH) and chronic kidney disease. Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research programme. This commitment is advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination product approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil UK/Global    +44 203 749 5637 Burrows Vanessa UK/Global    +44 203 749 5736 Rhodes Karen UK/Global    +44 203 749 5634 Birmingham Rob UK/Global    +44 203 749 5821 Skelding Jacob Lund    Sweden    +46 8 553 260 20 Michele US    +1 302 885 2677 Meixell Investor Relations UK Thomas Kudsk +44 203 749 5712 Larsen Craig Marks  Finance, Fixed Income, M&A +44 7881 615 764 Nick Stone  Respiratory & Autoimmunity +44 203 749 5716 Henry Oncology  +44 203 749 5797 Wheeler Christer Infection & Neuroscience +44 203 749 5711 Gruvris US Lindsey Cardiovascular & Metabolic   Diseases +1 240 543 7970 Trickett Mitchell  Oncology +1 240 477 3771 Chan Toll-free +1 866 381 7277 Adrian Kemp Company Secretary AstraZeneca PLC -ENDS-

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 191

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 95

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 77

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 171

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 72

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 23

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

evolv Consulting and Snowflake Join Forces in Automotive Tech

Updated Category News Views 205

evolv Consulting Partners with Snowflake for Automotive Innovation evolv Consulting empowers data-driven insights at scale for the automotive industry through Snowflake AI Data Cloud for Manufacturing. evolv Consulting, recognized as an Elite Snowflake Services partner, has announced a strategic collaboration with Snowflake to enhance the AI Data Cloud for Manufacturing...

Continue Reading
Martela Corporation Shares Decline: Key Updates and Implications

Updated Category News Views 158

Martela Corporation Reports Notable Changes in Shareholding Martela Corporation has recently seen significant transactions that impact its share structure, which is crucial information for investors. On a particular date, Isku-Yhtymä Oy made an important announcement regarding its shareholding in Martela. This report revealed that Isku-Yhtymä Oy had sold enough shares...

Continue Reading
Forecasting Growth in the Chlorine Trifluoride Market by 2032

Updated Category News Views 221

Overview of the Chlorine Trifluoride Market Chlorine trifluoride is emerging as a pivotal player in numerous high-tech applications, with the market anticipated to reach a staggering USD 82.81 million by 2032. This significant growth is fueled by an annual compound growth rate (CAGR) of 4.64% from the previous years. The reactivity of chlorine trifluoride makes it an...

Continue Reading
Ryde Group's Public Offering: Key Insights and Developments

Updated Category News Views 274

Ryde Group Ltd (NYSE American: RYDE) made waves in the market with its public offering valued at approximately $4.5 million. The offering encompassed 5.3 million units, each comprising one Class A Ordinary Share plus a warrant that can be exercised into an additional Ordinary Share at $0.85. With warrants exercisable immediately and valid for five years, traders keen on...

Continue Reading
Citi's Optimistic Forecast for Enel Stock Amid Renewables Growth

Updated Category News Views 145

Citi's Optimistic Outlook on Enel Recently, Citi reaffirmed its strong Buy rating on Enel (BIT: ENEI) SpA stock, maintaining a price target of EUR7.40. This renewed confidence comes ahead of the company's anticipated third-quarter earnings announcement slated for early November. Analysts at Citi predict that Enel is poised to deliver robust financial results, prompting...

Continue Reading